Yatharth Hospital & Trauma Care Services growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024
+37.1%+31.3%+80.5%
+32.6%+22.4%+70.9%
+25.3%+8.3%+62.6%
+30.5%+14.0%+78.4%
+23.6%+1.8%+47.1%
+31.8%+69.8%+109.8%
+10.4%+87.2%+377.9%
+36.7%+4,960.4%−104.8%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

YATHARTH₹923.30

Yatharth Hospital & Trauma Care Services Ltd.

· Pharma & Health
₹ CrorePeersMAXHEALTHMEDANTAFORTISVIYASHTHYROCARESUPRIYASTARSPARCMcap ₹8,896 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—+80.5+31.3+37.1—
EBITDA Growth—+70.9+22.4+32.6—
EBIT Growth—+62.6+8.3+25.3—
Net Income Growth—+78.4+14.0+30.5—
EPS Growth—+47.1+1.8+23.6—
Total Assets Growth—+109.8+69.8+31.8—
Total Equity Growth—+377.9+87.2+10.4—
Cash from Operations Growth—-104.8+4,960.4+36.7—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.